VRDNViridian Therapeutics, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+15.2% YoY

Gross Profit

-$6M-242.0% margin

Operating Income

-$9M-355.7% margin

Net Income

-$9M-353.9% margin

EPS (Diluted)

$-4.31

QoQ Revenue Growth

+575.8%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$49M

Total Liabilities

$15M

Stockholders' Equity

$33M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+15.2%
Gross Profit	-$6M	-$6M	+1.7%
Operating Income	-$9M	-$9M	-0.9%
Net Income	-$9M	-$9M	-2.1%

Revenue Segments

Collaboration Revenue

$2M50%

Reimbursement Revenue

$2M50%

Grant

$16,0000%

VRDN Q2 2019 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena